Hovione and international product development company Industrial Design Consultancy Ltd (IDC) have announced that their lead single-use nasal dry powder device from the pair's Intranasal Drug Delivery Platform is now available for commercial partnerships.
Hovione and IDC said in a joint statement that they have now completed device design and established manufacturing capabilities, enabling pharmaceutical partners to use existing capsule-filling infrastructure.
This will simplify development, lower costs and risk and shorten timelines for clinical and commercial use.
This milestone marks the platform's transition to commercial partnerships, enabling pharmaceutical partners to accelerate their intranasal programmes with a fully integrated solution that includes API development, particle engineering, manufacturing and device supply.
The single-use nasal dry powder device is also protected by a dedicated intellectual property portfolio with initial patent grants.
Additionally, Hovione and IDC are developing a multi-dose variant to broaden the platform's applicability across different therapies and dosing regimens.
"This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform," said Dr Márcio Temtem, Vice President, Strategic Business Management, Hovione.
As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical.
"By bringing together nasal particle engineering science, formulation manufacturing and filling and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies."
The nasal delivery device provides targeted and flexible nasal deposition with high usability and reliability.
Its patented design is now available for exclusive partnerships with pharmaceutical companies as part of Hovione’s solutions for inhalation and nasal drug development.
IDC’s Managing Director, Dr Stephen Knowles, added: "Our partnership with Hovione has already delivered a successful single-use device suitable for a range of therapies and our joint team can support pharma customers to use the device to bring new nasal therapies to market."
Additionally, we are now well-advanced with the development of a multi-use device to support an even wider range of therapies and patient needs.
The collaboration provides a comprehensive intranasal solution by integrating capabilities in API development, particle engineering, formulation, capsule filling, drug manufacturing and device design.
The pair said that the streamlined approach reduces technology transfer requirements and provides pharmaceutical partners with a single, unified platform.
Respiratory Drug Delivery 2026
Hovione will present additional insights on its Intranasal Drug Delivery Platform at the Respiratory Drug Delivery 2026 conference.
The workshop will provide an overview of developing next-generation nasal powder products, focusing on advanced formulation and particle engineering strategies to address challenges in nasal delivery.
It will also discuss essential in vitro and analytical tools to guide development and ensure regulatory readiness.
The workshop will be held on May 12, 2026, at the Westin Kierland in Phoenix, Arizona, USA.